Lakefront Biotherapeutics (LKFT) EBT Margin (2014 - 2026)
Lakefront Biotherapeutics (LKFT) posted quarterly EBT Margin of 215.34% for Q1 2026, up 42389.0% year-over-year from N/an in Q1 2025, and up 147.69% quarter-over-quarter from 86.94% in Q4 2025.
Powered by 
Analysis
Lakefront Biotherapeutics (LKFT) EBT Margin (2014 - 2026) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has reported EBT Margin for 13 consecutive years, with 215.34% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT Margin rose 42389.0% year-over-year to 215.34%; the TTM figure through Mar 2026 stood at 44.6% (up 12454.0% YoY), while the FY2025 annual figure was 27.05%, up 2817.0% from the prior year.
- EBT Margin advanced to 215.34% in Q1 2026 per LKFT's latest filing, from 86.94% in the prior quarter.
- Across five years, EBT Margin topped out at 239.96% in Q2 2025 and bottomed at 678.61% in Q3 2025.
- Historically, EBT Margin has averaged 59.9% across 5 years, with a median of 35.02% in 2022.
- Annual changes were most pronounced in 2022 — EBT Margin jumped 273065 bps — and 2025, when it tumbled 62924 bps.
- Lakefront Biotherapeutics' EBT Margin stood at 35.02% in 2022, then decreased by 9 bps to 38.07% in 2023, then soared by 535 bps to 165.49% in 2024, then tumbled by 47 bps to 86.94% in 2025, then jumped by 148 bps to 215.34% in 2026.
- Business Quant data shows LKFT's EBT Margin at 215.34% in Q1 2026, 86.94% in Q4 2025, and 678.61% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | Lakefront Biotherapeutics | 1.88 Bn | 1.88 Bn | 3.51 Mn | -358.92% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -358.92% |
| Mar 31, 2026 | 215.34% |
| Dec 31, 2025 | 33,453.14% |
| Sep 30, 2025 | -678.61% |
| Jun 30, 2025 | 239.96% |
| Mar 31, 2025 | -208.55% |
| Dec 31, 2024 | -8,167.69% |
| Sep 30, 2024 | -57.26% |
| Jun 30, 2024 | -191.84% |
| Mar 31, 2024 | 36.74% |
| Dec 31, 2023 | 1,025.49% |
| Sep 30, 2023 | -23.23% |
| Jun 30, 2023 | -22.49% |
| Mar 31, 2023 | -19.43% |
| Dec 31, 2022 | 41,940.10% |
| Sep 30, 2022 | -27.58% |
| Jun 30, 2022 | -55.47% |
| Mar 31, 2022 | -8.50% |
| Dec 31, 2021 | -4.95% |
| Sep 30, 2021 | -55.27% |